Evidence map›Paper›PMID 41250830›Full record

ArticleJournal of cellular and molecular medicine2025

Protection From Demyelination by the Novel Adenosine Dual A

M Morozzi, F Cherchi, C Sasia, L Frulloni, G Videtta, M Venturini, D Catarzi, F Varano, S Calenda, C Ceni and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Protection From Demyelination by the Novel Adenosine Dual AJournal of cellular and molecular medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

M MorozziSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
F CherchiSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
C SasiaSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
L FrulloniSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
G VidettaSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
M VenturiniSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
D CatarziSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
F VaranoSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
S CalendaSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
C CeniSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
G VagnoniSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
V ColottaSection of Pharmaceutical and Nutraceutical Sciences, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Sesto Fiorentino, Italy.
E CoppiSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
A M PuglieseSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.
N GaleottiSection of Pharmacology and Toxicology, Department of Neurosciences, Psychology, Drug Research and Child Health (Neurofarba), University of Florence, Florence, Italy.ORCID 0000-0002-1812-9844

Funding

Ente Cassa di Risparmio di FirenzeFondazione Italiana Sclerosi Multipla -cod.2024/R-Single/038NextGenerationEU and Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP) CUP B83C22003920001
6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory disease characterised by myelin and axonal loss. Lack of remyelination is primarily attributed to the failure of oligodendrocyte progenitor cells (OPCs) to differentiate into mature oligodendrocytes. The neuromodulator adenosine can influence OPC differentiation, and by selectively stimulating A

Indexed as

Adenosine A2 Receptor AntagonistsDemyelinating DiseasesEncephalomyelitis, Autoimmune, ExperimentalOligodendrocyte Precursor CellsReceptor, Adenosine A2AReceptor, Adenosine A2BAnimalsCell DifferentiationCells, CulturedFemaleMiceMice, Inbred C57BLMyelin SheathOligodendrogliaSpinal CordAdenosine A2 Receptor AntagonistsReceptor, Adenosine A2AReceptor, Adenosine A2Badenosine receptorsautoimmune experimental encephalomyelitisdemyelinationmultiple sclerosisoligodendrocyte progenitor cellspain

Identifiers

PMID41250830
PMCPMC12623459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.